Blueprint Medicines saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 67 to 76.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Blueprint Medicines can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Blueprint Medicines is building a consolidation with a 121.90 entry. See if the stock can clear the breakout price in volume at least 40% above average.
Blueprint Medicines posted 0% earnings growth last quarter, while sales growth came in at 127%.
The company earns the No. 81 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
